Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
8405138
Reference Type
Journal Article
Title
HPLCæ³æµå®çé ¸å¡æ¿æ´å°æ»´ç¼æ¶²æå ³ç©è´¨
Author(s)
Li, ZY; Liu, Y; Liu, W
Year
2020
Publisher
Chinese Journal of New Drugs Co. Ltd.
Volume
29
Issue
11
Page Numbers
1297-1300
Language
Chinese
Abstract
Objective: To establish a method for the determination of related substances in carteolol hydrochloride eye drops by high performance liquid chromatography (HPLC) and improve the quality standards of the eye drops. Methods: HPLC method was developed with ODS C18 (250 mmÃ4.6 mm, 5 μm) as the chromatographic column and eluted at a flow rate of 1.0 mLâ¢min-1 with mobile phase consisting of methanol-acetonitrile-2.82 gâ¢L-1 sodium hexane sulfonate solution(10:200:790). The column temperature, detection wavelength and the injection volume were set at 30 â, 252 nm and 20 μL, respectively. Results: Carteolol hydrochloride and impurity H were completely separated. The impurity H showed a good linear relationship with the peak area of the chromatogram in the range of 0.02~20.0 μgâ¢mL-1 (r=1.000 0). The correction factor of impurity H was 0.62. The acceleration and long-term stability tests of carteolol hydrochloride eye drops were carried out using the developed method. All the results were within the qualified range and no significant change was observed. Conclusion: The method is reliable, effective, high sensitive, fast detectable and can be used to detect related substances of carteolol hydrochloride eye drops. © 2020, Chinese Journal of New Drugs Co. Ltd. All right reserved.
Keywords
Carteolol hydrochloride; HPLC; Quality control; Quality standard; Related substances
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity